Vol. 5 No. 11 (2025)
Reimbursement Recommendations

Guselkumab (Tremfya)

decorative image of the issue cover

Published November 13, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Tremfya be reimbursed by public drug plans for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), if certain conditions are met.
  • Tremfya should only be covered for a patient population similar to that eligible for other advanced therapies for UC (e.g., biologics, sphingosine 1-phosphate receptor modulators, or Janus kinase [JAK] inhibitors) currently reimbursed by public drug plans.
  • Tremfya should only be reimbursed if it is prescribed by a physician experienced in the diagnosis and management of UC, and if it is not used in combination with other advanced therapies for UC. A patient’s disease must respond to treatment in the first 24 weeks of starting Tremfya to continue receiving the drug. The cost of Tremfya should not exceed the drug program cost of treatment with the least costly advanced therapy reimbursed for the treatment of UC.